We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Protein Identified in Fast-Metastasizing Tumors

By Biotechdaily staff writers
Posted on 08 May 2006
Researchers have discovered a protein that may explain why tumors in a low-oxygen environment are more lethal.

The findings, published April 27, 2006, in the journal Nature, revealed that tumors that are hypoxic (low in oxygen) make a protein called lysyl oxidase that helps the tumor metastasize to other organs. Lysyl oxidase (LOX), could be a good target for future cancer therapies, according to the researchers.

"All tumors have the potential to spread,” said lead author Amato Giaccia, M.D., professor of radiation oncology from the Stanford University School of Medicine (CA, USA). "A low-oxygen environment dials up that potential, and now we know why.”

Hypoxia is caused when the supply of oxygen from the bloodstream cannot meet demand from body tissues and tumors. Hypoxic tumors can be found in many areas of the body. For this study, the researchers evaluated both breast tumors and head and neck tumors. In each case, patients whose tumors produced high levels of LOX were more apt to have tumors that metastasize and to die of the disease.

To answer the question as to whether blocking LOX could also slow the cancer's spread, the researchers grew human tumors that produced high levels of LOX in mice. Using three different methods of blocking LOX production, they found that the tumors were less likely to spread than tumors producing LOX unimpeded.

According to Dr. Giaccia, blocking LOX in patients with hypoxic tumors has great potential as a new therapy. He added that there are several ways of determining whether a tumor is hypoxic and therefore likely to be producing LOX. Furthermore, one of the methods used to block LOX in mice was an antibody, the same type of protein as HER2/Neu, which has drastically improved outcomes in individuals with some types of breast tumors.

A therapy that specifically targets tumors producing LOX would be especially promising given that these are frequently among the most lethal cancers. Dr. Giaccia reported that trials in humans could begin as soon as 2009. The group is now looking at the relationship between LOX production and hypoxia in other types of tumors including colon and lung.



Related Links:
Stanford University School of Medicine

New
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
New
Repetitive Pipette
VWR® Stepper Pro
New
Automated Urinalysis Solution
UN-9000

Latest BioResearch News

Study Identifies Protein Changes Driving Immunotherapy Resistance in Multiple Myeloma
08 May 2006  |   BioResearch

Genetic Analysis Identifies BRCA-Linked Risks Across Multiple Cancers
08 May 2006  |   BioResearch

Study Identifies Hidden B-Cell Mutations in Autoimmune Disease
08 May 2006  |   BioResearch